

Supplementary Figure S1

a

Antibody Santa Cruz Biotechnology (sc-13143) raised against amino acids 468-689 of human GRK2 (78 % matches)

```

huGRK2      468  ppIpprgevnaadafdigsfdeedtkgikllsdqelyrnfpltiSERWQGEVAVTfdtinaetdrlEARkKaknkqlgheedyalgkdcimhgymsKmgnpfltqwqrryfyfnpR
huGRK3-1    468  ppIpprgevnaadafdigsfdeedtkgikllsdqelyknfplviSERWQGEVtvtvyeavnadtDKIeArkraknkqlgheedyalgkdcimhgymlKlgnpfltqwqrryfyfnpR

huGRK2      588  lewrgegeapgslltmeelqSveetqikerkdillkIrggkqfilgdsdpelvgwkkelrdayreaqqlvgrvpmknkprspvvelskvpIvgrgsangl
huGRK3-1    588  lewrgegesrgnlltmeelqSveetqikdkkdillfrIrggkqfvlqesdpsfvqwkkelnetfkeagrllrIapkfInkprsgtvelpksIchrng-hgl
  
```

b

Antibody Cell Signaling Technology (#3982) raised against amino-terminal residues of human GRK2 is cross-reactive with overexpressed GRK3-1 (77 % matches)

```

huGRK2      1  madleavladvsylmamekskatpaarasKkllIpepsirsvmgkyledrgevtfeKifsqklyllfrdfclnhleearplvefyeeikkyekleteeervarsrelfdsyimkellac
huGRK3-1    1  madleavladvsylmamekskatpaarasKkrlvlIpepsirsvmgkylaerngaitfdkiInqkigflfkdfclneineavpqqkfyeeikkyekldneedrIcrrsqiydayimkellsc
  
```

c

Antibody Cell Signaling Technology (#80362) raised against amino acids surrounding lysine 454 (red) of GRK3 slightly detects overexpressed GRK6-1, 6-2, and 6-3 (35 % matches)

```

huGRK3-1    400  hEIdrmtltvnvelpdtfSpelkslllegllqrdvskrlgchggsgsevkehshffIgvdqwhvylqkypplIpprgevnaadafdigsfdeedtkgikl
huGRK6-1    395  eEvdrrvIeteevyshkfseeaksickmlltkdakrIlgdqeegaevkrhpfrrnmnfkrleagmldpgfvdpvayckvldieqfs--stvkgvnl
  
```

Antibody Cell Signaling Technology (#80362) raised against amino acids surrounding lysine 454 (red) of GRK3 slightly detects overexpressed GRK5 (34 % matches)

```

huGRK3-1    400  hEIdrmtltvnvelpdtfSpelkslllegllqrdvskrlgchggsgsevkehshffIgvdqwhvylqkypplIpprgevnaadafdigsfdeedtkgikl
huGRK5      395  eEvdrrvIeteevyshkfseeaksickmlltkdakrIlgdqeegaevkrhpfrrnmnfkrleagmldpgfvdpvayckvldieqfs--stvkgvnl
  
```

d


Antibody Cell Signaling Technology (#5878) raised against amino acids surrounding glutamic acid 69 (red) of GRK6 slightly detects overexpressed GRK5 (59 % matches)

```

huGRK6-1    30  wrqmqIqfphisqceelrlsleRdyhslcerpIgrllfrfEcatrpeIIsrcvafldgvaeyevtpdkrkacgrqltqnfI
huGRK5      30  wkeilIqfphisqcedlrltidRdyCSldkqIgrllfrqfCetrpggIecyidfldsvaeyevtpdekIgekqkeimtKyl
  
```

Supplementary Figure S1: Alignment of protein sequences used to create designated antibodies and the corresponding sequence of the indicated GRK isoform which are also detected by the antibody. Amino acids identical in both sequences are highlighted in green. Total identity is denoted in per cent. **a** Alignment of human GRK2 and human GRK3-1 protein sequences from amino acid 468 to 689 which are both recognized by antibody sc-13143 (Santa Cruz Biotechnology). **b** Alignment of human GRK2 and human GRK3-1 protein sequences from the first amino acid to amino acid 120 which are both recognized by antibody CS #3982 (Cell Signaling Technology). **c** Alignment of human GRK3-1 with human GRK6-1 and GRK5 protein sequences from amino acid 400 to 499 and 395 to 494, respectively. Antibody CS #80362 (Cell Signaling Technology) was raised against GRK3 but also detects GRK6-1, -2, -3 and GRK5. **d** Alignment of human GRK6-1 and human GRK5 protein sequences from amino acid 30 to 499 which are both recognized by antibody CS #5878 (Cell Signaling Technology).

Supplementary Figure S2



Supplementary Figure S2:

HEK293 cells were transfected with either empty vector (EV), GRK2 (**a**), 3 (**b**), 5 (**c**), and 6 isoforms (**d**) or their corresponding kinase-dead variants GRK2-K220R (**a**), GRK3-1-K220R (**b**), GRK5-K215R (**c**), and GRK6-1-K215R (**d**). Lysates were prepared in presence (+) or absence (-) of phosphatase inhibitors and EDTA. Western blot analysis of the lysates using the indicated antibodies was performed.

Supplementary Figure S3

GRK2

a Antibody Santa Cruz Biotechnology (sc-13143) raised against amino acids 468-689 of human GRK2

huGRK2	468	pplipprgeevnaadafdigsfdeedtkgikllsdqelyrnflptiserwqgevaetvfdtinaetdrlearkkakknlqgheedyalgkdcimhgymskmgnpfltqwrrryfylfpnr	
muGRK2-1	468	pplipprgeevnaadafdigsfdeedtkgikllsdqelyrnflptiserwqgevaetvfdtinaetdrlearkkakknlqgheedyalgkdcivhgymskmgnpfltqwrrryfylfpnr	
ratGRK2	468	pplipprgeevnaadafdigsfdeedtkgikllsdqelyrnflptiserwqgevaetvfdtinaetdrlearkkakknlqgheedyalgkdcimhgymskmgnpfltqwrrryfylfpnr	
hamGRK2-x2	468	pplipprgeevnaadafdigsfdeedtkgikllsdqelyrnflptiserwqgevaetvfdtinaetdrlearkkakknlqgheedyalgkdcimhgymskmgnpfltqwrrryfylfpnr	
monGRK2	468	pplipprgeevnaadafdigsfdeedtkgikllsdqelyrnflptiserwqgevaetvfdtinaetdrlearkkakknlqgheedyalgkdcimhgymskmgnpfltqwrrryfylfpnr	
huGRK2	588	lewrgegeapqslltmeeiqsveetqikerkcillkirggkqfvlqcdsdpeivqwkkelrdayreaqqlvqrvpkmknkprspvvelskvplvqrgsangl	
muGRK2-1	588	lewrgegeapqslltmeeiqsveetqikerkcillkirggkqfvlqcdsdpeivqwkkelrdayreaqqlvqrvpkmknkprspvvelskvplvqrgsangl	98 % identity to huGRK2
ratGRK2	588	lewrgegeapqslltmeeiqsveetqikerkcillkirggkqfvlqcdsdpeivqwkkelrdayreaqqlvqrvpkmknkprspvvelskvplvqrgsangl	98 % identity to huGRK2
hamGRK2-x2	588	lewrgegeapqslltmeeiqsveetqikerkcillkirggkqfvlqcdsdpeivqwkkelrdayreaqqlvqrvpkmknkprspvvelskvplvqrgsangl	99 % identity to huGRK2
monGRK2	588	lewrgegeapqslltmeeiqsveetqikerkcillkirggkqfvlqcdsdpeivqwkkelrdayreaqqlvqrvpkmknkprspvvelskvplvqrgsangl	99 % identity to huGRK2

b Antibody Cell Signaling Technology (#3982) raised against amino-terminal residues of human GRK2

huGRK2	1	madleavladvsylmamekskatpaaraskillpepsirsvmqyledrgevtfekifsqklgyllfrdfclnhleaarpvlfeyeeikkyekleteeervrsreifdsyimkellac	
muGRK2-1	1	madleavladvsylmamekskatpaaraskillpepsirsvmqyledrgevtfekifsqklgyllfrdfclnhleaarpvlfeyeeikkyekleteeervrsreifdsyimkellac	98 %
ratGRK2	1	madleavladvsylmamekskatpaaraskillpepsirsvmqyledrgevtfekifsqklgyllfrdfcynhleaarpvlfeyeeikkyekleteeervrsreifdsyimkellac	96 %
hamGRK2-x2	1	madleavladvsylmamekskatpaaraskillpepsirsvmqyledrgevtfekifsqklgyllfrdfcynhleaarpvlfeyeeikkyekleteeervrsreifdsyimkellac	97 %
monGRK2	1	madleavladvsylmamekskatpaaraskillpepsirsvmqyledrgevtfekifsqklgyllfrdfcynhleaarpvlfeyeeikkyekleteeervrsreifdsyimkellac	100 %

Supplementary Figure S3: Alignment of human, mouse, rat, hamster, and monkey GRK2 protein sequences from amino acid 468 to 689 (a) and 1 to 120 (b). Differing amino acids are highlighted in yellow. Total identity is denoted in per cent.

Supplementary Figure S4

GRK3

Antibody Cell Signaling Technology (#80362) raised against amino acids surrounding lysine 454 (red)

```
huGRK3-1      400 heidrmtltvnvlpdtfspelksllegllqrdvskrlgchgggsqevkehsffgvdwqhvyllqkyppplipprgevnaadafdigsfdeedtkgiklld
muGRK3-1      400 heidrmtltvnvlpdafspelsllegllqrdvsrlgcgggarelkehiffgldwqhvyllkyppplipprgevnaadafdigsfdeedtkgiklld 89 %
ratGRK3       400 heidrmtltvnvlpdafspelsllegllqrdvskrlgcgggarelkehiffgldwqyvylkyppplipprgevnaadafdigsfdeedtkgiklld 88 %
hamGRK3-x3    400 heidrmtltvnvlpdafspelsllegllqrdvskrlgcgggqsqevkehsffgldwqhvyllkyppplipprgevnaadafdigsfdeedtkgiklld 90 %
monGRK3-x1    400 heidrmtltvnvlpdtfspelksllegllqrdvskrlgchgggsqevkehsffgvdwqhvyllqkyppplipprgevnaadafdigsfdeedtkgiklld 100 %
```

Supplementary Figure S4: Alignment of human, mouse, rat, hamster, and monkey GRK3 protein sequences from amino acid 400 to 100. Differing amino acids are highlighted in yellow. Total identity is denoted in per cent.

Supplementary Figure S5

GRK5

Antibody Santa Cruz Biotechnology (sc-518005) raised against amino acids 94-157 of human GRK5

```
huGRK5      94 pdeklgekqkeimtkyltpkspvfiagvgqdlvsqteekllqkpkelfsacaqsvheylrgep
muGRK5      94 pdellgakgkeimtkyltpkspvfiagvgqdlvsqtekllqspckelfsacaqsvhdylkgdp 89 %
ratGRK5      94 pdellgakgkeimtkylspkspvfiagvgqdlvsqtekllqspckelfsacaqsvhdylkgdp 87 %
hamGRK5-3    94 pdellgekgkeitkyltpkspvfiagvgqdlvsqteallqspckelfsacaqsvhdylkgdp 89 %
monGRK5      94 pdeklgekqkeimskyltpkspvfiagvgldlvseteekllqkpkelfsacaqsvheylrgep 95 %
```

Supplementary Figure S5: Alignment of human, mouse, rat, hamster, and monkey GRK5 protein sequences from amino acid 94 to 157. Differing amino acids are highlighted in yellow. Total identity is denoted in per cent.

Supplementary Figure S6

GRK6

a Antibody Cell Signaling Technology (#5878) raised against amino acids surrounding glutamic acid 69 (red) for GRK6

```
huGRK6-1      30 wrqmlqfphisqceelrslslerdyhslcerqpigrllfrfcatrpe|sr|cvafldgvaeyevtpddkrkacgrqltgnfl
muGRK6-3     30 wrqmlqfphisqceelrslslerdyhslcerqpigrllfrfcatrpe|sr|cvafldgvaeyevtpdekrkacgrqlmgnfl 92 %
ratGRK6-3    30 wrqmlqfphisqceelrslslerdyhslcerqpigrllfrfcatrpe|sr|cvafldgvaeyevtpdekrkacgrqlmgnfl 93 %
hamGRK6-x1   30 wrqmlqfphisqceelrslslerdyhslcerqpigrllfrfcatrpe|sr|cvafldgvaeyevtpdekrkacgrqlmgnfl 93 %
monGRK6-x1   30 wrqmlqfphisqceelrslslerdyhslcerqpigrllfrfcatrpe|sr|cvafldgvaeyevtpdekrkacgrqlmgnfl 96 %
```

b Antibody Boster Biological Technology (PB9709) raised against amino acids 382-417 of human GRK6

```
huGRK6-1      382 qspfqqrkkkikreeverlvkevpeeyserfspqar
muGRK6-3     382 qspfqqrkkkikreeverlvkevpeeyserfspqar 88 %
ratGRK6-3    382 qspfqqrkkkikreeverlvkevpeeyserfspqar 91 %
hamGRK6-x1   382 qspfqqrkkkikreeverlvkevpeeyserfspqar 97 %
monGRK6-x1   382 qspfqqrkkkikreeverlvkevpeeyserfspqar 100 %
```

Supplementary Figure S6: Alignment of human, mouse, rat, hamster, and monkey GRK6 protein sequences from amino acid 30 to 110 (a) and 382 to 417 (b). Differing amino acids are highlighted in yellow. Total identity is denoted in per cent.

